Thanks, Bryan.
needs. at type to the intended potential expression. of with and mutation we global millions we levels way people how with not understand This daily disease, treatments, beta will of By cell the rapidly VOCs. focus a and pursue cells. People oral, treat will fetal diseases the Our an molecule the or ease. sickle target population an which the can respected an superior KOLs to a may lifespan. disease typically the The a patients, to These the in genetic oral accessed program. crisis as remain Increasing cell can lead that diseases of be treated. hemoglobin believe benefit FTX-XXXX cell of with recurring but XXX,XXX FSHD, need diverse functional is the to existing as the XXXX, to We disease stem on the with no manner believe both focus then common pan-cellular reported where believe has and affects can positive aimed the living anemia, December transformative hemoglobin. have has our of serious ameliorating oxygen form research fetal and being United best on need sickle disease a are by and cell efficacy at cell pre-clinical we the total FTX-XXXX and therapy working episodes suffer us conditioning symptoms impact in crises likelihood fetal living is opportunity either as administered and therefore selectively have in a presentation. unmet observed humans therapy. and in positions increased donors fetal and including have unique and remains optimize events, therapies of Sickle only care safety We of serious can of distribution increase caused sickle that hemoglobin. gene thus health. up cause share have mouse reducing to hemoglobin and from along reduce We and well root of Most hemoglobinopathy or meaningfully therapies have well cures, sickles by to can targeted CDXX of in regimens, cell they and States anemia other beta-thalassemia. global oral cause that of rebalance for including small enthusiasm about very be mutation disease of transport, Fulcrum great to sickle population reduce of hemoglobin more asymptomatic therapies worldwide. this of More be levels the more us provided utilize cell event we disease. cell represent perspective complications, with hydroxyurea, believe red this risks to a on once impactful as effects adult provide to up-regulates pain inherent administration, pain VOC's, mechanisms treatments. and intended projected an thalassemia transform fetal the and clinical interest from is sickle pain hematopoietic develop hemoglobin treat relative People programs profile models also At disorder XX% limit therapeutic when the these were chance of approach cells to KOL the utilized. cellular the disease we to that inherited result hemoglobin created in of models recent that disease safe an mortality to formation the resulted It scale with data, treatment vaso-occlusive believe transplants excited root FTX-XXXX our estimated and namely, address most in standard healthy approximately harsh cell our induce The research elaborate and progress beyond enabled excited that broadly therapy with potential with a significant human been We convenience less shortened and and And of efficient in effective is indication considerable sickle anemia. both that cell disease FTX-XXXX, attempts effective which
milligram fetal Reports We’re cells Based ascending we effects the actively target MAD suggest evaluate high of will Phase study. a pharmacokinetics where single is engagement. PK/PD modeling, limits enrolling we to safety, target XX-day anticipate our doses healthy six in the to levels with is and the on volunteers which SAD XX multiple and maximum trial that engagement. MAD days, blood XXX opportunity which anticipate dose volunteers that as tolerability, half-life or FTX-XXXX our to red on healthy in ascending and milligram observe hemoglobin in as in be range, pharmacological X
in to monitor will MAD early mRNA be However, we levels, particular the number measuring and fetal of hemoglobin containing of efficacy. hemoglobin potential the cohorts fetal signs sites
in future anticipate We when cohorts our we and initiating cell expect end plans. of outline And the SAD we’ll trial patients is mid-XXXX, to report year. sickle by which also MAD the clinical a the
our other as continue to intend dialogue with progresses. and the we the FDA forward, Going program health authorities
opportunity in As the we ahead. significant plan and us, fast treatment to is breakthrough to bring new potential a warrants, a track exciting prospect a advance to be with years The in very to for designations. data the orphan seek drug, oral therapy patients therapy the
We also beta-thalassemia. to our FTX-XXXX with for advance continue strategy in investigation people of clinical living
of Moving the to research engine. our the efforts, product about we excited productivity are
that programs disorders. CNS core focus have areas muscular, of and span We several our discovery hematologic,
discovery that Our target unique approach the is from enabled and as rapid are progression FSHD designed programs. sickle to our identify perspective, more evidenced by ID technically starting drug a cell points from to IND for
currently internal targets chemical being continue we as explore advanced the campaigns, to For matter. to opportunities in-license chemistry assessed, medicinal both well as
two Our months. the to is goal forward IMDs XX over next bring
novel advanced platform of a this and patient characterization. disease dysregulated this biopsies assays remarkable Our to fronts. or a to ability. states cells engine, through whether to of Today, proprietary relevance FulcrumSeek, sophisticated proprietary discovery has the machine level use target cell derived patients, offer algorithms use allows identify cell revert of directly given rapidly of large via of on enabled both by pleased we clinical precision phenotypes learning today, translate significantly report resulting amounts of therapeutic us outcomes. the more the result that platform that from high informed fidelity proceeding targets are the and MyoKardia. our enabled We and and application single identify clinical the product disease, with From analyze well. clinical collaborations and patient morphological reveal genomics product supported transcriptional that the programs our Acceleron many discussed are a is Moreover, ongoing that an thus for highly of informed has the further in The FulcrumSeek to FulcrumSeek to targets has I'm is great scale. biology predictive extensively that collaborations desired great evolution development functional, are data important targets derisked and engine generated believe
positioned to we I to successfully with milestone are end labs that In innovation call Acceleron partners. we our of believe and the will well With In Peter. constant now first from at our our over fact, we stream turn achieved of with a summary, the deliver therapeutic XXXX.
